Table 2 HIV-related characteristics of HIV-infected participants by HBV infection status (N = 2419)
From: Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada
Clinical Characteristics | HIV N = 2220 | HIV-HBV Co-Infected N = 199 | p valuea |
|---|---|---|---|
Baseline HIV viral load (Log10 copies/mL) | |||
  < 4 | 332 (15) | 30 (15) | 0.87 |
 4–5 | 1011 (46) | 94 (47) |  |
  > 5 | 877 (40) | 75 (38) |  |
End of follow-up HIV viral load (Log10 copies/mL) | |||
  < 4 | 2104 (95) | 193 (97) | 0.38 |
 4–5 | 69 (3) | 4 (2) |  |
  > 5 | 47 (2) | 2 (1) |  |
Baseline CD4 T cell count (cells/mm3) | 235 (120–360) | 188 (85–294) | 0.0002 |
Baseline CD4 T cell count category (cells/mm3) | |||
  ≤ 199 | 897 (40) | 105 (53) | 0.002 |
 200–349 | 720 (32) | 60 (30) |  |
 350–499 | 367 (17) | 24 (12) |  |
  > 500 | 236 (11) | 10 (5) |  |
Baseline AIDS-Defining Illnessb | |||
  ≥ 1 | 446 (20) | 55 (28) | 0.01 |
 None | 1774 (80) | 144 (72) |  |
Years on ARV therapy | 5.01 (2.50–8.75) | 5.97 (3.11–9.94) | 0.003 |
HIV Suppressed since FARVDT | 2040 (92) | 190 (96) | 0.07 |
HIV Rebound (since first VS) | 481 (24) | 56 (29) | 0.07 |